Head-to-head · WeighScore
SexyMD vs The Edit
The verdict
The Edit takes it — 70.4/100 to 60.3/100.
The Edit grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The Edit holds one price at every dose, charges nothing to start, refunds in full if you are not approved, and then says none of its published policies actually govern.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | SexyMD | The Edit |
|---|---|---|
| WeighScore | 60.3/100 | 70.4/100 |
| Grade | C | C |
| Scorecard rank | #353 | #113 |
| Semaglutide | $269/mo (four-week plan; the $199 in every headline is the 48-week rate) | $259/mo (standing rate, flat at every dose; $200 covers the first month only) |
| Tirzepatide | $369/mo (four-week plan; the $299 in every headline is the 48-week rate) | $349/mo (standing rate, flat at every dose; $300 covers the first month only) |
| Coverage | 47 states (all except Arkansas, Mississippi and New Jersey) | All 50 states (claimed; hedged in the same paragraph, no list published) |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #353 · C
Strengths
- Publishes an exact exclusion list — all states except Arkansas, Mississippi and New Jersey — rather than a nationwide claim
- States both compounding classes in the Terms, so the class question is answered even though the pharmacy is not named
- Names the prescribing entity and the professional corporation behind it
- Sells two microdose products with their own published price tables rather than only as a discount tier
Where it loses points
- Every headline price is the 48-week commitment rate: $199 against a month-to-month figure of $269, and $299 against $369, with an asterisk that resolves to no footnote
- The same footer, on every page, says both that the service is available in all 50 states and that it is available in all states except three
- The two microdose products publish identical prices for their 4-, 8- and 12-week plans, in the same table format that carries real tiers elsewhere
- The microdose page contradicts itself on dosing frequency inside a single page
- Three unsourced and mutually inconsistent social-proof figures appear across the homepage, the footer and the product pages
- The checkout claims two patient counts for a single day that together exceed the total the site's own badge claims
- No pharmacy is named, and what the price includes is never itemized on any product page
Graded #113 · C
Strengths
- The price is flat at every dose with no titration ladder, so the figure a reader sees is the figure at maintenance
- Nothing is charged and no card is taken to begin, and a full refund applies if a clinician does not approve treatment
- Names its medical director with an NPI number and the medical practice behind him, and names a dispensing pharmacy
- Prescription medication, injection supplies, the clinician visit and ongoing care are itemized as included, with no membership fee
- A separate hormone menu is priced beside the GLP-1 lines
Where it loses points
- $200 and $300 are first-order promotional prices printed larger than the struck standing rates of $259 and $349, and the promotion carries no end date and no code
- The published cancellation and refund policies say the Membership Agreement controls where they differ, and that nothing on the public site is binding — so the terms a reader can read are not the terms that apply
- Two-day shipping is transit time only; the site's own shipping policy states an average of 4 to 12 business days from prescription
- “Available in all 50 U.S. states” is hedged in the same paragraph and no state list is published anywhere
- The three- and six-month figures are one charge, not a monthly rate, and the per-month numbers beside them are arithmetic rather than billing
- The named pharmacy is described as one member of a plural pharmacy network whose other members are not named
- No compounding class is stated, and whether a separate visit fee is ever charged is not answered
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 536 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.